14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Redeye initiates commissioned research on FluoGuide


October 12, 2021

Copenhagen, Denmark, 12 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with the Swedish investment bank Redeye AB (Redeye) on commissioned research coverage.


Starting today, Redeye has initiated its commissioned research, meaning that Redeye will continuously monitor and analyze FluoGuide’s operations, its products, markets, and competitors.

The initial research report is available here